Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.It didn’t happen the way Immutep might have hoped for, but the company is taking its Lag3 project eftilagimod alpha into a phase 3 lung cancer trial at last. The bull case was that Immutep would attract a lucrative licensing deal – or even a buyout – but in the event it was investors who had to stump up the cash for the phase 3 to be run by Immutep alone and without a partner.
https://www.oncologypipeline.com/apexonco/node/695
Ann: Webcast slides for new Efti clinical data in 1st line HNSCC, page-86
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.005(1.64%) |
Mkt cap ! $454.5M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.8¢ | 30.8¢ | $401.5K | 1.283M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 496512 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 48690 | 7 |
View Market Depth
| Last trade - 13.36pm 17/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |